Rami Doukky et al. JCHF 2016;4:24-35

Slides:

Advertisements

Similar presentations

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Advertisements

Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Quality of Care of and Outcomes for African Americans.

A Statewide Collaborative Initiative to Improve the Quality of Care for Patients With Acute Myocardial Infarction and Heart Failure Circulation. 2009;119:

From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

Fig ACCF/AHA Guideline for the management of heart failure

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

The American Heart Association

Diabetes Mellitus and Heart Failure

Clyde W. Yancy et al. JACC 2017;70:

Clyde W. Yancy et al. JACC 2017;70:

Figure 1 Energy supply–demand matching in health and heart failure

Deborah J. Clegg, PhD, Michael Cody, MD, Biff F. Palmer, MD

Eugene Braunwald JCHF 2013;1:1-20

Shadi Al Halabi et al. JACEP 2015;1:

Orly Vardeny et al. JCHF 2014;2:

Sexual Activity and Chronic Heart Failure

Johannes Steiner et al. JACC 2017;70:

John E. Sanderson JCHF 2014;2:93-94

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Fig. 2. Evidence-based medication prescriptions

Nat. Rev. Cardiol. doi: /nrcardio

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Wayne L. Miller et al. JCHF 2013;1:

Mohit K. Turagam et al. JACEP 2017;3:

Konstantinos C. Siontis et al. JACEP 2016;2:

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

Jordan B. King et al. JCHF 2016;4:

G. Michael Felker et al. JCHF 2014;2:

Connie W. Tsao et al. JCHF 2016;4:

Rami Doukky et al. JCHF 2016;4:24-35

Gordon R. Reeves et al. JCHF 2017;j.jchf

Peter E. Carson et al. JCHF 2015;3:

Maria R. Costanzo et al. JCHF 2016;4:

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Emilce Trucco et al. JACEP 2018;j.jacep

Ali Ahmed, MD, MPH, Michael W. Rich, MD, Michael Zile, MD, Paul W

Ali Ahmed, MD, Gregg C. Fonarow, MD, Yan Zhang, MS, MSPH, Paul W

Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure Cherinne Arundel,

Jordan B. King et al. JCHF 2016;4:

Svend A. Mortensen et al. JCHF 2014;2:

Connie W. Tsao et al. JCHF 2016;4:

EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART.

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Immunosuppression significantly reduced all-cause mortality or risk of ESRD (A) and significantly increased complete or partial remission (B) at the end.

Christian Madelaire et al. JCHF 2018;6:

William T. Abraham et al. JCHF 2018;j.jchf

Satoru Kishi et al. JCHF 2014;2:

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

Constantijn Franssen et al. JCHF 2016;4:

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Dennis M. McNamara et al. JCHF 2014;2:

Jackson J. Liang et al. JCHF 2014;2:

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Propensity score-matching

Orly Vardeny et al. JCHF 2016;4:

Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.

An updated general approach for achieving BP goals in people with diabetes. An updated general approach for achieving BP goals in people with diabetes.

Maria R. Costanzo et al. JCHF 2016;4:

Adjusted hazard ratio (AHR) of final AVF failure by percent consistent facility aspirin use. Adjusted hazard ratio (AHR) of final AVF failure by percent.

β-Blocker Use for the Stages of Heart Failure

Percentage of patients found with a kidney function too low for recommended use of the drug using estimated glomerular filtration rate compared with creatinine.

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Kernel density plots of propensity score distributions in the included and excluded populations. Kernel density plots of propensity score distributions.

Flow diagram of the recommended pharmacological management of heart failure adapted from the European Society of Cardiology guidelines Flow diagram.

Constantijn Franssen et al. JCHF 2016;4:

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Presentation transcript:

Rami Doukky et al. JCHF 2016;4:24-35 Absolute Standardized Differences in Baseline Covariates Between Sodium-Restricted and Unrestricted Patients Before and After Propensity Score Matching ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; HART = Heart Failure Adherence and Retention Trial; HFrEF = heart failure with reduced ejection fraction; NYHA = New York Heart Association; SF-36 = 36-Item Short Form Health Survey. Rami Doukky et al. JCHF 2016;4:24-35 American College of Cardiology Foundation